Avian retroviral protease and cellular aspartic proteases are distinguished by activities on peptide substrates. 1989

M Kotler, and W Danho, and R A Katz, and J Leis, and A M Skalka
Fox Chase Cancer Center, Institute for Cancer Research, Philadelphia, Pennsylvania 19111.

The avian sarcoma/leukemia virus protease (PR), purified from avian myeloblastosis virus has a native molecular mass of 26 kDa, suggesting a dimer structure. The enzymatic activity of PR has been characterized using synthetic peptide substrates. PR is most active at pH 5.5, 35 degrees C and 2-3 M NaCl. Under these conditions PR cleaves decapeptides which are resistant in low ionic strength. This high, nonphysiological, salt concentration also increases the proteolytic activity of a cellular aspartic protease, pepsin. PR and pepsin show additional similarities: they both cleave a synthetic decapeptide at the same Tyr-Pro bond in low and high salt, while the cleavage site preferences of human renin and cathepsin-D in this substrate are altered at high salt concentrations. In addition, iodination of the tyrosine residue in this decapeptide causes an increase in the rates of hydrolysis by both PR and pepsin. However, Km values are too high to be estimated accurately for PR using Tyr-Pro and Tyr(I)-Pro decapeptides as substrates. Comparison of the digestion products of two additional decapeptides, altered in a single amino acid residue, shows that PR cleaves at fewer sites than all three cellular enzymes. Furthermore pepstatin, a strong inhibitor of pepsin, renin, and cathepsin-D has little effect on PR.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D009189 Avian Myeloblastosis Virus A species of ALPHARETROVIRUS causing anemia in fowl. Myeloblastosis Virus, Avian,Avian Myeloblastosis Viruses,Myeloblastosis Viruses, Avian,Virus, Avian Myeloblastosis,Viruses, Avian Myeloblastosis
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D009994 Osmolar Concentration The concentration of osmotically active particles in solution expressed in terms of osmoles of solute per liter of solution. Osmolality is expressed in terms of osmoles of solute per kilogram of solvent. Ionic Strength,Osmolality,Osmolarity,Concentration, Osmolar,Concentrations, Osmolar,Ionic Strengths,Osmolalities,Osmolar Concentrations,Osmolarities,Strength, Ionic,Strengths, Ionic
D010434 Pepsin A Formed from pig pepsinogen by cleavage of one peptide bond. The enzyme is a single polypeptide chain and is inhibited by methyl 2-diaazoacetamidohexanoate. It cleaves peptides preferentially at the carbonyl linkages of phenylalanine or leucine and acts as the principal digestive enzyme of gastric juice. Pepsin,Pepsin 1,Pepsin 3
D010436 Pepstatins N-acylated oligopeptides isolated from culture filtrates of Actinomycetes, which act specifically to inhibit acid proteases such as pepsin and renin.
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010447 Peptide Hydrolases Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES. Peptidase,Peptidases,Peptide Hydrolase,Protease,Proteases,Proteinase,Proteinases,Proteolytic Enzyme,Proteolytic Enzymes,Esteroproteases,Enzyme, Proteolytic,Hydrolase, Peptide
D011392 Proline A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons. L-Proline,L Proline

Related Publications

M Kotler, and W Danho, and R A Katz, and J Leis, and A M Skalka
May 2006, Proceedings of the National Academy of Sciences of the United States of America,
M Kotler, and W Danho, and R A Katz, and J Leis, and A M Skalka
March 2005, Journal of the American Chemical Society,
M Kotler, and W Danho, and R A Katz, and J Leis, and A M Skalka
February 1990, Science (New York, N.Y.),
M Kotler, and W Danho, and R A Katz, and J Leis, and A M Skalka
February 1989, Nature,
M Kotler, and W Danho, and R A Katz, and J Leis, and A M Skalka
January 2017, Methods in molecular biology (Clifton, N.J.),
M Kotler, and W Danho, and R A Katz, and J Leis, and A M Skalka
January 1998, Advances in experimental medicine and biology,
M Kotler, and W Danho, and R A Katz, and J Leis, and A M Skalka
July 2020, Biomolecules,
M Kotler, and W Danho, and R A Katz, and J Leis, and A M Skalka
January 1994, Methods in enzymology,
M Kotler, and W Danho, and R A Katz, and J Leis, and A M Skalka
January 1999, Dermatology (Basel, Switzerland),
Copied contents to your clipboard!